Elicera Therapeutics AB (8E8) Price & Analysis

0 Followers

8E8 Stock Chart & Stats

€0.47

€0.03(20.86%)

At close: Jan 08 4:00 PM EST

€0.47

€0.03(20.86%)

Day’s Range― - ―

52-Week Range€0.18 - €0.67

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€14.54M

Enterprise Value€239.86

Total Cash (Recent Filing)€17.86M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.64

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding66,736,374

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free capital structure materially lowers refinancing and interest-rate risk, giving management flexibility to prioritize R&D and strategic partnerships. Over 2–6 months this provides durable optionality to time equity raises or collaborations rather than being forced into costly debt financing.

High Gross Margin PotentialReported strong gross-margin characteristics suggest the company’s therapeutic products could scale to high-margin revenue once commercialized. Durable margin advantages support long-term profitability potential if development succeeds and operating expenses are managed during commercialization.

Specialized Cell & Gene Therapy FocusA focused pipeline in next‑generation cell and gene therapies (CAR T, persistence tech) targets high unmet need areas like solid tumors and hematologic cancers. This specialization creates durable competitive barriers and high-value commercialization opportunities if clinical development progresses.

Bears Say

High Cash BurnSustained negative operating and free cash flow around -27.8m TTM indicates heavy ongoing funding needs. Over the coming months this structural cash burn pressures runway, forces frequent capital raises, risks dilution, and can constrain consistent investment in development programs.

Very Low And Declining RevenueModest revenue that has declined sharply shows limited commercial traction and an inability to offset R&D spend. Structurally, low recurring revenue increases dependence on financing for operations and reduces near-term prospects for self-sustaining growth or reinvestment into clinical programs.

Deep Ongoing Losses And Negative ReturnsExtremely negative margins and deeply negative ROE reflect structural unprofitability driven by high operating costs vs revenue. Over a multimonth horizon this erodes equity, heightens dilution risk, and means success depends on clinical progress or funding rather than internal earnings generation.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.18 and its highest was €0.67 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €14.54M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 12 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 66,736,374 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.677%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.